ARS Pharmaceuticals, Inc. — Director's Dealing 2024

Jan 4, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2023-05-17

Reporting Person: Lowenthal Richard E (Director, President and CEO, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-05-17	Common Stock	G	1050000	$0.00	Disposed	4126822	Direct
2023-05-17	Common Stock	G	1050000	$0.00	Acquired	1050000	Indirect
2023-05-17	Common Stock	G	1050000	$0.00	Disposed	3276854	Indirect
2023-05-17	Common Stock	G	1050000	$0.00	Acquired	2100000	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-01-02	Stock option (right to buy)	$5.58	A	880000	Acquired	2034-01-01	Common Stock (880000)	Direct
2024-01-02	Stock option (right to buy)	$5.58	A	300000	Acquired	2034-01-01	Common Stock (300000)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1772850	Indirect
Common Stock	1772850	Indirect

Footnotes

F1: These shares are held in a trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust.

F2: The Reporting Person is trustee of the trust.

F3: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F4: 25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years.